Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 1

3(42.9%)

Phase 3

1(14.3%)

7Total

Phase 2(3)

Phase 1(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02763254Phase 2Terminated

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

Role: lead

NCT01948180Phase 2Terminated

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

Role: lead

NCT01621724Phase 1Completed

WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study

Role: lead

NCT02550535Phase 1Completed

A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients

Role: lead

NCT02873325Terminated

Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT

Role: lead

NCT01077908Phase 3Completed

Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study

Role: lead

NCT01822093Phase 1Completed

Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT

Role: lead

NCT01220895Phase 2Completed

Alternate Donor Study of Pre-Emptive Cellular Therapy

Role: lead

All 8 trials loaded